公开(公告)号：US20250011779A1

公开(公告)日：2025-01-09

申请号：US18697901

申请日：2022-10-04

Applicant: AMGEN INC.

Inventor： Jiamiao LU ,  Michael OLLMANN ,  Patrick COLLINS ,  Chi-Ming LI ,  Songli WANG

IPC: C12N15/113

Abstract: The present invention relates to compositions and methods for enhancing the gene silencing activity of oligonucleotide compounds. In particular, the invention relates to inhibiting the expression or activity of suppressor proteins, such as RAB18, ZW10, STX18, SCFD2, NAPG, SAMD4B, or VPS37A, to increase the efficacy of ligand-conjugated oligonucleotide compounds in reducing the expression of target genes in a cell.

公开(公告)号：US20230279399A1

公开(公告)日：2023-09-07

申请号：US18007560

申请日：2021-06-03

Applicant: Amgen Inc.

Inventor： Daniel C. H. LIN ,  Michael OLLMANN ,  Justin K. MURRAY ,  Bradley J. HERBERICH ,  Amrita DAS ,  Patrick COLLINS ,  Oliver HOMANN

IPC: C12N15/113

CPC classification number: C12N15/1137 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/315 ,  C12N2310/11

Abstract: The present invention relates to RNAi constructs for reducing expression of the HSD17B13 gene. Methods of using such RNAi constructs to treat or prevent liver disease, nonalcoholic fatty liver disease (NAFLD) are also described.